Antimicrobial Coating for Biofilm Inhibition

用于抑制生物膜的抗菌涂层

• 批准号: 6485882
• 负责人: H. RALPH RAWLS
• 金额: $ 10万
• 依托单位: BIOMEDICAL DEVELOPMENT CORPORATION
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-01 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6485882
• 关键词: Candida; antifungal agents; antiinfective agents; drug delivery systems; drug design /synthesis /production; intramuscular injections; laboratory rabbit; molecular film; nosocomial infection control; polyvinyls; surface coating

Description(provided by applicant): Candida is the third leading cause of catheter-related nosocomial bloodstream infections. Indwelling devices have been shown to support colonization and biofilm formulation by Candida. Intravenous lines are the most frequent indwelling device and are the single most common cause of candidemia. Once a Candida biofilm forms in vivo, removal of the substrate that is supporting the biofilm growth is almost always required to eliminate the infection. Unfortunately, in many instances removal is impossible due to deteriorated patient condition, anatomical location, or underlying disease. The goal of this project is to incorporate an antifungal agent into unique, patented formulations to create a coating for medical devices that is resistant to C. albicans. A coating and antifungal delivery system that could extend the time and/or increase the rate of delivery and achieve a higher concentration of antifungal agents to a C. albicans-susceptible site would have enormous therapeutic advantages over systemic and inefficacious topical routes of delivery. To demonstrate the feasibility of this approach, the specific aims are to optimize the coating formulation for use as short-term antifungal coatings for medical devices, evaluate the coatings for antifungal activity in vitro, and to perform an intramuscular implantation study in rabbits. PROPOSED COMMERCIAL APPLICATION: Candida albicans is by far the most frequently isolated human mycotic agent. The large number of immunosuppressed patients with indwelling devices combined with the extensive social and economic costs associated with treating C. albicans-related infections serve as justification for the pursuit of alternative therapies.

描述（由申请人提供）：念珠菌是导致感染的第三大原因 导管相关的医院血流感染。留置装置有 已被证明支持念珠菌的定植和生物膜形成。 静脉导管是最常用的留置装置，也是唯一的留置装置 念珠菌血症的最常见原因。一旦念珠菌生物膜在体内形成，去除 几乎总是需要支持生物膜生长的基质来消除感染。不幸的是，在许多情况下，删除 由于患者状况、解剖位置恶化或 原发疾病。 该项目的目标是将抗真菌剂融入独特的、 专利配方，用于为医疗器械创建耐腐蚀涂层 白色念珠菌。一种涂层和抗真菌输送系统，可以延长 时间和/或增加递送速率并实现更高的浓度 抗真菌剂对白色念珠菌敏感部位会产生巨大的影响 相对于全身和无效的局部途径的治疗优势 送货。为了证明该方法的可行性，具体目标 优化用作短期抗真菌剂的涂料配方 医疗器械涂层，评估涂层的抗真菌活性 体外，并在兔子中进行肌内植入研究。 拟议的商业应用：白色念珠菌是迄今为止最常分离的人类真菌病原体。 大量使用留置装置的免疫抑制患者，加上与治疗白色念珠菌相关感染相关的广泛社会和经济成本，成为寻求替代疗法的理由。